Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.44
BMRN's Cash to Debt is ranked higher than
57% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. BMRN: 1.44 )
BMRN' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 1.44

Equity to Asset 0.61
BMRN's Equity to Asset is ranked higher than
68% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BMRN: 0.61 )
BMRN' s 10-Year Equity to Asset Range
Min: -0.4   Max: 0.95
Current: 0.61

-0.4
0.95
F-Score: 4
Z-Score: 12.40
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -12.37
BMRN's Operating margin (%) is ranked higher than
80% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. BMRN: -12.37 )
BMRN' s 10-Year Operating margin (%) Range
Min: -1075   Max: 13.41
Current: -12.37

-1075
13.41
Net-margin (%) -17.84
BMRN's Net-margin (%) is ranked higher than
78% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. BMRN: -17.84 )
BMRN' s 10-Year Net-margin (%) Range
Min: -1025   Max: 54.7
Current: -17.84

-1025
54.7
ROE (%) -9.18
BMRN's ROE (%) is ranked higher than
80% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. BMRN: -9.18 )
BMRN' s 10-Year ROE (%) Range
Min: -751.65   Max: 39.6
Current: -9.18

-751.65
39.6
ROA (%) -5.65
BMRN's ROA (%) is ranked higher than
82% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. BMRN: -5.65 )
BMRN' s 10-Year ROA (%) Range
Min: -76.62   Max: 18.88
Current: -5.65

-76.62
18.88
ROC (Joel Greenblatt) (%) -14.22
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. BMRN: -14.22 )
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -433   Max: 24.82
Current: -14.22

-433
24.82
Revenue Growth (3Y)(%) 9.20
BMRN's Revenue Growth (3Y)(%) is ranked higher than
81% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BMRN: 9.20 )
BMRN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.7
Current: 9.2

0
97.7
EPS Growth (3Y)(%) 24.20
BMRN's EPS Growth (3Y)(%) is ranked higher than
90% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BMRN: 24.20 )
BMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 36.5
Current: 24.2

0
36.5
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BMRN Guru Trades in Q1 2014

John Burbank 5,173 sh (New)
Manning & Napier Advisors, Inc 171,510 sh (New)
Ray Dalio 48,400 sh (New)
PRIMECAP Management 8,163,719 sh (+7.98%)
John Griffin 2,060,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 9,737,665 sh (-4.87%)
Columbia Wanger 1,389,000 sh (-32.08%)
Steven Cohen 62,853 sh (-82.46%)
» More
Q2 2014

BMRN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 244,060 sh (+42.30%)
Frank Sands 11,925,248 sh (+22.47%)
John Griffin 2,100,000 sh (+1.94%)
Steven Cohen 90,100 sh (unchged)
John Burbank Sold Out
Ray Dalio Sold Out
PRIMECAP Management 8,064,219 sh (-1.22%)
Columbia Wanger 1,167,800 sh (-15.93%)
» More
Q3 2014

BMRN Guru Trades in Q3 2014

Joel Greenblatt 3,885 sh (New)
Paul Tudor Jones 5,913 sh (New)
Steven Cohen 675,600 sh (+649.83%)
Manning & Napier Advisors, Inc 288,180 sh (+18.08%)
John Griffin 2,230,000 sh (+6.19%)
Frank Sands 12,098,628 sh (+1.45%)
PRIMECAP Management 8,043,918 sh (-0.25%)
Columbia Wanger 853,800 sh (-26.89%)
» More
Q4 2014

BMRN Guru Trades in Q4 2014

Louis Moore Bacon 56,100 sh (New)
RS Investment Management 94,400 sh (New)
Frank Sands 12,183,113 sh (+0.70%)
Frank Sands 12,183,113 sh (+0.70%)
John Griffin 2,230,000 sh (unchged)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.60
BMRN's P/B is ranked lower than
53% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. BMRN: 11.60 )
BMRN' s 10-Year P/B Range
Min: 3.68   Max: 28.5
Current: 11.6

3.68
28.5
P/S 23.56
BMRN's P/S is ranked higher than
58% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. BMRN: 23.56 )
BMRN' s 10-Year P/S Range
Min: 3.37   Max: 94.86
Current: 23.56

3.37
94.86
EV-to-EBIT -210.27
BMRN's EV-to-EBIT is ranked lower than
58% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: -210.27 )
BMRN' s 10-Year EV-to-EBIT Range
Min: -1611.4   Max: 67133.8
Current: -210.27

-1611.4
67133.8
Current Ratio 6.05
BMRN's Current Ratio is ranked higher than
78% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. BMRN: 6.05 )
BMRN' s 10-Year Current Ratio Range
Min: 1.22   Max: 17.58
Current: 6.05

1.22
17.58
Quick Ratio 5.20
BMRN's Quick Ratio is ranked higher than
76% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. BMRN: 5.20 )
BMRN' s 10-Year Quick Ratio Range
Min: 1.18   Max: 17.58
Current: 5.2

1.18
17.58
Days Inventory 527.06
BMRN's Days Inventory is ranked higher than
76% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 527.06 )
BMRN' s 10-Year Days Inventory Range
Min: 106.92   Max: 917.29
Current: 527.06

106.92
917.29
Days Sales Outstanding 70.21
BMRN's Days Sales Outstanding is ranked higher than
81% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. BMRN: 70.21 )
BMRN' s 10-Year Days Sales Outstanding Range
Min: 50.96   Max: 212.92
Current: 70.21

50.96
212.92

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 92.30
BMRN's Price/Net Current Asset Value is ranked higher than
53% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. BMRN: 92.30 )
BMRN' s 10-Year Price/Net Current Asset Value Range
Min: 4.77   Max: 208.24
Current: 92.3

4.77
208.24
Price/Tangible Book 13.50
BMRN's Price/Tangible Book is ranked higher than
51% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. BMRN: 13.50 )
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.15   Max: 103.23
Current: 13.5

2.15
103.23
Price/DCF (Projected) 56.80
BMRN's Price/DCF (Projected) is ranked higher than
88% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 56.80 )
BMRN' s 10-Year Price/DCF (Projected) Range
Min: 25.77   Max: 234.29
Current: 56.8

25.77
234.29
Price/Median PS Value 1.50
BMRN's Price/Median PS Value is ranked higher than
75% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. BMRN: 1.50 )
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.21
Current: 1.5

0.38
4.21
Earnings Yield (Greenblatt) -0.50
BMRN's Earnings Yield (Greenblatt) is ranked higher than
83% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. BMRN: -0.50 )
BMRN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.5   Max: 3.3
Current: -0.5

-0.5
3.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 05 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 


More From Other Websites
BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April... Apr 14 2015
BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April... Apr 14 2015
Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but... Apr 10 2015
The Oprahs Of Biotech: People Who Can Go By First Name Only Apr 10 2015
Billionaire John Griffin’s Five Picks That Killed the Market This Quarter Apr 09 2015
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits Apr 03 2015
Retrophin Hits High On Bullish Initiation Report Apr 02 2015
Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog Apr 01 2015
Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame Mar 31 2015
Biotech's next buzz: Gene therapy? Mar 31 2015
How bubbles are blown: Biotech edition Mar 31 2015
Cramer tackles a tough tweet Mar 30 2015
BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical... Mar 30 2015
BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical... Mar 30 2015
BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape Mar 30 2015
BioMarin Pharma Hits All-Time High Mar 27 2015
BioMarin jumps after analyst suggests merger may be in its future Mar 27 2015
Equities snapped its four day losing streak... Mar 27 2015
Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks... Mar 27 2015
BioMarin Pharmaceutical (BMRN) Stock Gains Today on Merger Rumors Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK